Cytokines and growth factors

Recent Advances in IgA Nephropathy

Volumn , Issue , 2009, Pages 243-265

  Floege, Jurgen ^a   Ostendorf, Tammo ^a  

^a RWTH AACHEN UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 79952041661     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1142/9789812835871_0018     Document Type: Chapter

References (123)

1. Floege J, Mertens P (2000) Therapy of patients with IgA-nephropathy: a critical appraisal. Kidney Blood Press Res 23: 207-209.
2. Floege J, Feehally J. (2000) IgA nephropathy: recent developments. J Am Soc Nephrol 11: 2395-2403.
3. Floege J, Eitner F. (2005) Present and future therapy options in IgA- nephropathy. J Nephrol 18: 354-361.
4. Lai KN. (2002) Future directions in the treatment of IgA nephropathy. Nephron 92: 263-270.
5. Lai AS, Lai KN. (2005) Molecular basis of IgA nephropathy. Curr Mol Med 5: 475-487.
6. Lai KN, Ho RT, Leung JC, et al. (1994) CD4-positive cells from patients with IgA nephropathy demonstrate increased mRNA of cytokines that induce the IgA switch and differentiation. J Pathol 174: 13-22.
7. van den Dobbelsteen ME, van der Woude FJ, Schroeijers WE, et al. (1994) Binding of dimeric and polymeric IgA to rat renal mesangial cells enhances the release of interleukin 6. Kidney Int 46: 512-519.
8. Duque N, Gomez-Guerrero C, Egido J. (1997) Interaction of IgA with Fc alpha receptors of human mesangial cells activates transcription factor nuclear factor-kappa B and induces expression and synthesis of monocyte chemoattractant protein-1, IL-8, and IFN-inducible protein 10. J Immunol 159: 3474-3482.
9. Leung JC, Tang SC, Chan LY, et al. (2003) Polymeric IgA increases the synthesis of macrophage migration inhibitory factor by human mesangial cells in IgA nephropathy. Nephrol Dial Transplant 18: 36-45.
10. Chan LY, Leung JC, Tsang AW, et al. (2005) Activation of tubular epithelial cells by mesangial-derived TNF-alpha: glomerulotubular communication in IgA nephropathy. Kidney Int 67: 602-612.
11. Gesualdo L, Pinzani M, Floriano JJ, et al. (1991) Platelet-derived growth factor expression in mesangial proliferative glomerulonephritis. Lab Invest 65: 160-167.
12. Niemir ZI, Stein H, Noronha IL, et al. (1995) PDGF and TGF-beta contribute to the natural course of human IgA glomerulonephritis. Kidney Int 48: 1530-1541.
13. Floege J, Eitner F, Alpers CE. (2008) A new look at platelet-derived growth factor in renal disease. J Am Soc Nephrol 19: 12-23.
14. Floege J, Burg M, Al Masri AN, et al. (1999) Expression of interferon- inducible Mx-proteins in patients with IgA nephropathy or Henoch- Schonlein purpura. Am J Kidney Dis 33: 434-440.
15. Liu XQ, Paterson AD, He N, et al. (2008) IL5RA and TNFRSF6B gene variants are associated with sporadic IgA nephropathy. J Am Soc Nephrol 19: 1025-1033.
16. Oortwijn BD, Roos A, Royle L, et al. (2006) Differential glycosylation of polymeric and monomeric IgA: a possible role in glomerular inflammation in IgA nephropathy. J Am Soc Nephrol 17: 3529-3539.
17. Leung JC, Tang SC, Chan LY, et al. (2008) Synthesis of TNF-alpha by mesangial cells cultured with polymeric anionic IgA — role of MAPK and NF-kappaB. Nephrol Dial Transplant 23: 72-81.
18. Harada K, Akai Y, Kurumatani N, et al. (2002) Prognostic value of urinary interleukin 6 in patients with IgA nephropathy: an 8-year follow-up study. Nephron 92: 824-826.
19. Ranieri E, Gesualdo L, Petrarulo F, et al. (1996) Urinary IL-6/EGF ratio: a useful prognostic marker for the progression of renal damage in IgA nephropathy. Kidney Int 50: 1990-2001.
20. Eitner F, Westerhuis R, Burg M, et al. (1997) Role of interleukin-6 in mediating mesangial cell proliferation and matrix production in vivo. Kidney Int 51: 69-78.
21. Grandaliano G, Gesualdo L, Ranieri E, et al. (1996) Monocyte chemotactic peptide-1 expression in acute and chronic human nephritides: a pathogenetic role in interstitial monocytes recruitment. J Am Soc Nephrol 7: 906-913.
22. Yokoyama H, Wada T, Furuichi K, et al. (1998) Urinary levels of chemokines (MCAF/MCP-1, IL-8) reflect distinct disease activities and phases of human IgA nephropathy. J Leukoc Biol 63: 493-499.
23. Yoshioka K, Takemura T, Murakami K, et al. (1993) In situ expression of cytokines in IgA nephritis. Kidney Int 44: 825-833.
24. Chen HC, Tomino Y, Yaguchi Y, et al. (1992) Oxidative metabolism of polymorphonuclear leukocytes (PMN) in patients with IgA nephropathy. J Clin Lab Anal 6: 35-39.
25. Wada T, Yokoyama H, Tomosugi N, et al. (1994) Detection of urinary interleukin-8 in glomerular diseases. Kidney Int 46: 455-460.
26. Sekikawa T, Kashihara N, Maruyama K, et al. (1998) Expression of interleukin-8 in human glomerulonephritis. Res Commun Mol Pathol Pharmacol 99: 217-224.
27. Peichl P, Ceska M, Broell H, et al. (1992) Human neutrophil activating peptide/interleukin 8 acts as an autoantigen in rheumatoid arthritis. Ann Rheum Dis 51: 19-22.
28. Calandra T, Bernhagen J, Metz CN, et al. (1995) MIF as a glucocorticoid- induced modulator of cytokine production. Nature 377: 68-71.
29. Lan HY, Yang N, Nikolic-Paterson DJ, et al. (2000) Expression of macrophage migration inhibitory factor in human glomerulonephritis. Kidney Int 57: 499-509.
30. Leung JC, Chan LY, Tsang AW, et al. (2004) Anti-macrophage migration inhibitory factor reduces transforming growth factor-beta 1 expression in experimental IgA nephropathy. Nephrol Dial Transplant 19: 1976-1985.
31. Lai KN, Leung JC, Chan LY, et al. (2008) Activation of podocytes by mesan- gial-derived TNF-{alpha}: glomerulo-podocytic communication in IgA nephropathy. Am J Physiol Renal Physiol 294: F945-F955.
32. Li X, Ponten A, Aase K, et al. (2000) PDGF-C is a new protease-activated lIgAnd for the PDGF alpha-receptor. Nat Cell Biol 2: 302-309.
33. Bergsten E, Uutela M, Li X, et al. (2001) PDGF-D is a specific, protease- activated lIgAnd for the PDGF beta-receptor. Nat Cell Biol 3: 512-516.
34. LaRochelle WJ, Jeffers M, McDonald WF, et al. (2001) PDGF-D, a new protease-activated growth factor. Nat Cell Biol 3: 517-521.
35. Hamada T, Ui-Tei K, Imaki J, et al. (2001) Molecular cloning of SCDGF-B, a novel growth factor homologous to SCDGF/PDGF-C/fallotein. Biochem Biophys Res Commun 280: 733-737.
36. Li X, Eriksson U. (2003) Novel PDGF family members: PDGF-C and PDGF-D. Cytokine Growth Factor Rev 14: 91-98.
37. Heldin CH, Westermark B. (1999) Mechanism of action and in vivo role of platelet-derived growth factor. Physiol Rev 79: 1283-1316.
38. Floege J, Johnson RJ. (1995) Multiple roles for platelet-derived growth factor in renal disease. Miner Electrolyte Metab 21: 271-282.
39. Barnes JL, Woodruff KA, Levine SP et al. (1996) Inhibition of mesangial cell proliferation by platelet factor 4. J Am Soc Nephrol 7: 991-998.
40. van Roeyen CR, Eitner F, Scholl T, et al. (2008) CCN3 is a novel endogenous PDGF-regulated inhibitor of glomerular cell proliferation. Kidney Int 73: 86-94.
41. Floege J, Topley N, Hoppe J, et al. (1991) Mitogenic effect of platelet- derived growth factor in human glomerular mesangial cells: modulation and/or suppression by inflammatory cytokines. Clin Exp Immunol 86: 334-341.
42. Shankland SJ, Pippin J, Flanagan M, et al. (1997) Mesangial cell proliferation mediated by PDGF and bFGF is determined by levels of the cyclin kinase inhibitor p27Kip1. Kidney Int 51: 1088-1099.
43. Eitner F, Ostendorf T, Van Roeyen C, et al. (2002) Expression of a novel PDGF isoform, PDGF-C, in normal and diseased rat kidney. J Am Soc Nephrol 13: 910-917.
44. van Roeyen CR, Ostendorf T, Denecke B, et al. (2006) Biological responses to PDGF-BB versus PDGF-DD in human mesangial cells. Kidney Int 69: 1393-1402.
45. Doi T, Vlassara H, Kirstein M, et al. (1992) Receptor-specific increase in extracellular matrix production in mouse mesangial cells by advanced gly- cosylation end products is mediated via platelet-derived growth factor. Proc Natl Acad Sci USA 89: 2873-2877.
46. Kanemoto K, Usui J, Tomari S, et al. (2003) Connective tissue growth factor participates in scar formation of crescentic glomerulonephritis. Lab Invest 83: 1615-1625.
47. Throckmorton DC, Brogden AP Min B, et al. (1995) PDGF and TGF-beta mediate collagen production by mesangial cells exposed to advanced glyco- sylation end products. Kidney Int 48: 111-117.
48. Burger A, Wagner C, Viedt C, et al. (1998) Fibronectin synthesis by human tubular epithelial cells in culture: effects of PDGF and TGF-beta on synthesis and splicing. Kidney Int 54: 407-415.
49. Floege J, Hudkins KL, Seifert RA, et al. (1997) Localization of PDGF alpha-receptor in the developing and mature human kidney. Kidney Int 51: 1140-1150.
50. Alpers CE, Seifert RA, Hudkins KL, et al. (1993) PDGF-receptor localizes to mesangial, parietal epithelial, and interstitial cells in human and primate kidneys. Kidney Int 43: 286-294.
51. Alpers CE, Hudkins KL, Ferguson M, et al. (1995) Platelet-derived growth factor A-chain expression in developing and mature human kidneys and in Wilms’ tumor. Kidney Int 48: 146-154.
52. Seifert RA, Alpers CE, Bowen-Pope DF (1998) Expression of platelet- derived growth factor and its receptors in the developing and adult mouse kidney. Kidney Int 54: 731-746.
53. Eitner F, Ostendorf T, Kretzler M, et al. (2003) PDGF-C expression in the developing and normal adult human kidney and in glomerular diseases. J Am Soc Nephrol 14: 1145-1153.
54. Changsirikulchai S, Hudkins KL, Goodpaster TA, et al. (2002) Platelet- derived growth factor-D expression in developing and mature human kidneys. Kidney Int 62: 2043-2054.
55. Ostendorf T, Van Roeyen CR, Peterson JD, et al. (2003) A fully human monoclonal antibody (CR002) identifies PDGF-D as a novel mediator of mesan- gioproliferative glomerulonephritis. J Am Soc Nephrol 14: 2237-2247.
56. Taneda S, Hudkins KL, Topouzis S, et al. (2003) Obstructive uropathy in mice and humans: potential role for PDGF-D in the progression of tubu- lointerstitial injury. J Am Soc Nephrol 14: 2544-2555.
57. Ding H, Wu X, Bostrom H, et al. (2004) A specific requirement for PDGF-C in palate formation and PDGFR-alpha signaling. Nat Genet 36: 1111-1116.
58. Leveen P Pekny M, Gebre-Medhin S, et al. (1994) Mice deficient for PDGF B show renal, cardiovascular, and hematological abnormalities. Genes Dev 8: 1875-1887.
59. Hellstrom M, Kal n M, Lindahl P, et al. (1999) Role of PDGF-B and PDGFR-beta in recruitment of vascular smooth muscle cells and pericytes during embryonic blood vessel formation in the mouse. Development 126: 3047-3055.
60. Lindahl P Hellstrom M, Kalen M, et al. (1998) Paracrine PDGF-B/PDGF- Rbeta signaling controls mesangial cell development in kidney glomeruli. Development 125: 3313-3322.
61. Soriano P (1994) Abnormal kidney development and hematological disorders in PDGF beta-receptor mutant mice. Genes Dev 8: 1888-1896.
62. Liao X, Escobedo JA, Williams LT. (1996) Viability of transgenic mice expressing a platelet derived growth factor (PDGF) antagonist in plasma. J Investig Med 44: 139-143.
63. Floege J, Hudkins KL, Davis CL, et al. (1998) Expression of PDGF alpha- receptor in renal arteriosclerosis and rejecting renal transplants. J Am Soc Nephrol 9: 211-223.
64. Floege J, Burns MW, Alpers CE, et al. (1992) Glomerular cell proliferation and PDGF expression precede glomerulosclerosis in the remnant kidney model. Kidney Int 41: 297-309.
65. Kliem V, Johnson RJ, Alpers CE, et al. (1996) Mechanisms involved in the pathogenesis of tubulointerstitial fibrosis in 5/6-nephrectomized rats. Kidney Int 49: 666-678.
66. Ranieri E, Gesualdo L, Grandaliano G, et al. (2001) The role of alpha- smooth muscle actin and platelet-derived growth factor-beta receptor in the progression of renal damage in human IgA nephropathy. J Nephrol 14: 253-262.
67. Waldherr R, Noronha IL, Niemir Z, et al. (1993) Expression of cytokines and growth factors in human glomerulonephritides. Pediatr Nephrol 7: 471-478.
68. Floege J, Eng E, Young BA, et al. (1993) Infusion of platelet-derived growth factor or basic fibroblast growth factor induces selective glomerular mesangial cell proliferation and matrix accumulation in rats. J Clin Invest 92: 2952-2962.
69. Hudkins KL, Gilbertson DG, Carling M, et al. (2004) Exogenous PDGF-D is a potent mesangial cell mitogen and causes a severe mesangial proliferative glomerulopathy. J Am Soc Nephrol 15: 286-298.
70. Johnson RJ, Raines EW, Floege J, et al. (1992) Inhibition of mesangial cell proliferation and matrix expansion in glomerulonephritis in the rat by antibody to platelet-derived growth factor. J Exp Med 175: 1413-1416.
71. Floege J, Ostendorf T, Janssen U, et al. (1999) Novel approach to specific growth factor inhibition in vivo: antagonism of platelet-derived growth factor in glomerulonephritis by aptamers. Am J Pathol 154: 169-179.
72. Nakamura H, Isaka Y, Tsujie M, et al. (2001) Electroporation-mediated PDGF receptor-IgG chimera gene transfer ameliorates experimental glomerulonephritis. Kidney Int 59: 2134-2145.
73. Takahashi T, Abe H, Arai H, et al. (2005) Activation of STAT3/Smad1 is a key signaling pathway for progression to glomerulosclerosis in experimental glomerulonephritis. J Biol Chem 280: 7100-7106.
74. Iruela-Arispe L, Gordon K, Hugo C, et al. (1995) Participation of glomerular endothelial cells in the capillary repair of glomerulonephritis. Am J Pathol 147: 1715-1727.
75. Ostendorf T, Kunter U, van Roeyen C, et al. (2002) The effects of platelet- derived growth factor antagonism in experimental glomerulonephritis are independent of the transforming growth factor-beta system. J Am Soc Nephrol 13: 658-667.
76. Gilbert RE, Kelly DJ, McKay T, et al. (2001) PDGF signal transduction inhibition ameliorates experimental mesangial proliferative glomerulonephritis. Kidney Int 59: 1324-1332.
77. Hirai T, Masaki T, Kuratsune M, et al. (2006) PDGF receptor tyrosine kinase inhibitor suppresses mesangial cell proliferation involving STAT3 activation. Clin Exp Immunol 144: 353-361.
78. Jayson GC, Parker GJ, Mullamitha S, et al. (2005) Blockade of platelet- derived growth factor receptor-beta by CDP860, a humanized, PEGylated di-Fab’, leads to fluid accumulation and is associated with increased tumor vascularized volume. J Clin Oncol 23: 973-981.
79. Piek E, Heldin CH, Ten Dijke P (1999) Specificity, diversity, and regulation in TGF-beta superfamily signaling. FASEB J 13: 2105-2124.
80. Blobe GC, Schiemann WP Lodish HF. (2000) Role of transforming growth factor beta in human disease. N Engl J Med 342: 1350-1358.
81. Li MO, Wan YY, Sanjabi S, et al. (2006) Transforming growth factor-beta regulation of immune responses. Annu Rev Immunol 24: 99-146.
82. Prud’homme GJ. (2007) Pathobiology of transforming growth factor beta in cancer, fibrosis and immunologic disease, and therapeutic considerations. Lab Invest 87: 1077-1091.
83. Sharma K, Ziyadeh FN. (1994) The emerging role of transforming growth factor-beta in kidney diseases. Am J Physiol 266: F829-F842.
84. Yang Z, Mu Z, Dabovic B, et al. (2007) Absence of integrin-mediated TGFbeta1 activation in vivo recapitulates the phenotype of TGFbeta1-null mice. J Cell Biol 176: 787-793.
85. Bottinger EP Bitzer M. (2002) TGF-beta signaling in renal disease. J Am Soc Nephrol 13: 2600-2610.
86. Kitamura M, Suto TS. (1997) TGF-beta and glomerulonephritis: antiinflammatory versus prosclerotic actions. Nephrol Dial Transplant 12: 669-679.
87. van Vlasselaer P, Punnonen J, de Vries JE. (1992) Transforming growth factor-beta directs IgA switching in human B cells. J Immunol 148: 2062-2067.
88. Bitzer M, von Gersdorff G, Liang D, et al. (2000) A mechanism of suppression of TGF-beta/SMAD signaling by NF-kappa B/RelA. Genes Dev 14: 187-197.
89. Floege J, Ostendorf T, Wolf G. (2001) Growth factors and cytokines. In: Immunologic Renal Diseases (eds.) Couser WG, Neilson EG. Lippincott- Raven, Philadelphia, pp. 415-463.
90. Shull MM, Ormsby I, Kier AB, et al. (1992) Targeted disruption of the mouse transforming growth factor-beta 1 gene results in multifocal inflammatory disease. Nature 359: 693-699.
91. Chen CA, Hwang JC, Guh JY, et al. (2006) TGF-beta1 and integrin syner- gistically facilitate the differentiation of rat podocytes by increasing alpha- smooth muscle actin expression. Transl Res 148: 134-141.
92. Schiffer M, Bitzer M, Roberts IS, et al. (2001) Apoptosis in podocytes induced by TGF-beta and Smad7. J Clin Invest 108: 807-816.
93. Chen S, Lee JS, Iglesias-de la Cruz MC, et al. (2005) Angiotensin II stimulates alpha3(IV) collagen production in mouse podocytes via TGF-beta and VEGF signalling: implications for diabetic glomerulopathy. Nephrol Dial Transplant 20: 1320-1328.
94. Abbate M, Zoja C, Morigi M, et al. (2002) Transforming growth factor- beta1 is up-regulated by podocytes in response to excess intraglomerular passage of proteins: a central pathway in progressive glomerulosclerosis. Am J Pathol 161: 2179-2193.
95. Yard BA, Chorianopoulos E, Herr D, et al. (2001) Regulation of endothelin- 1 and transforming growth factor-beta1 production in cultured proximal tubular cells by albumin and heparan sulphate glycosaminoglycans. Nephrol Dial Transplant 16: 1769-1775.
96. Wolf G, Schroeder R, Ziyadeh FN, et al. (2004) Albumin up-regulates the type II transforming growth factor-beta receptor in cultured proximal tubular cells. Kidney Int 66: 1849-1858.
97. Ostendorf T, Kunter U, Eitner F, et al. (1999) VEGF(165) mediates glomerular endothelial repair. J Clin Invest 104: 913-923.
98. Li ZD, Bork JP Krueger B, et al. (2005) VEGF induces proliferation, migration, and TGF-beta1 expression in mouse glomerular endothelial cells via mitogen-activated protein kinase and phosphatidylinositol 3- kinase. Biochem Biophys Res Commun 334: 1049-1060.
99. Wolf G, Schroeder R, Ziyadeh FN, et al. (1997) High glucose stimulates expression of p27Kip1 in cultured mouse mesangial cells: relationship to hypertrophy. Am J Physiol 273: F348-F356.
100. Li JM, Nichols MA, Chandrasekharan S, et al. (1995) Transforming growth factor beta activates the promoter of cyclin-dependent kinase inhibitor p15INK4B through an Sp1 consensus site. J Biol Chem 270: 26750-26753.
101. Isaka Y, Fujiwara Y, Ueda N, et al. (1993) Glomerulosclerosis induced by in vivo transfection of transforming growth factor-beta or platelet-derived growth factor gene into the rat kidney. J Clin Invest 92: 2597-2601.
102. Iwano M, Akai Y, Fujii Y, et al. (1994) Intraglomerular expression of transforming growth factor-beta 1 (TGF-beta 1) mRNA in patients with glomerulonephritis: quantitative analysis by competitive polymerase chain reaction. Clin Exp Immunol 97: 309-314.
103. Yoshioka K, Takemura T, Murakami K, et al. (1993) Transforming growth factor-beta protein and mRNA in glomeruli in normal and diseased human kidneys. Lab Invest 68: 154-163.
104. Lai KN, Tang SC, Guh JY, et al. (2003) Polymeric IgA1 from patients with IgA nephropathy upregulates transforming growth factor-beta synthesis and signal transduction in human mesangial cells via the renin- angiotensin system. J Am Soc Nephrol 14: 3127-3137.
105. Tomooka S, Border WA, Marshall BC, et al. (1992) Glomerular matrix accumulation is linked to inhibition of the plasmin protease system. Kidney Int 42: 1462-1469.
106. Kagami S, Border WA, Miller DE, et al. (1994) Angiotensin II stimulates extracellular matrix protein synthesis through induction of transforming growth factor-beta expression in rat glomerular mesangial cells. J Clin Invest 93: 2431-2437.
107. Shin GT, Kim SJ, Ma KA, et al. (2000) ACE inhibitors attenuate expression of renal transforming growth factor-beta1 in humans. Am J Kidney Dis 36: 894-902.
108. Zeisberg M, Hanai J, Sugimoto H, et al. (2003) BMP-7 counteracts TGF- beta1-induced epithelial-to-mesenchymal transition and reverses chronic renal injury. Nat Med 9: 964-968.
109. Sanderson N, Factor V, Nagy P, et al. (1995) Hepatic expression of mature transforming growth factor beta 1 in transgenic mice results in multiple tissue lesions. Proc Natl Acad Sci USA 92: 2572-2576.
110. Ziyadeh FN, Hoffman BB, Han DC, et al. (2000) Long-term prevention of renal insufficiency, excess matrix gene expression, and glomerular mesan- gial matrix expansion by treatment with monoclonal antitransforming growth factor-beta antibody in db/db diabetic mice. Proc Natl Acad Sci USA 97: 8015-8020.
111. Chen S, Iglesias-de la Cruz MC, Jim B, et al. (2003) Reversibility of established diabetic glomerulopathy by anti-TGF-beta antibodies in db/db mice. Biochem Biophys Res Commun 300: 16-22.
112. Ling H, Li X, Jha S, et al. (2003) Therapeutic role of TGF-beta-neutraliz- ing antibody in mouse cyclosporin A nephropathy: morphologic improvement associated with functional preservation. J Am Soc Nephrol 14: 377-388.
113. Yu L, Border WA, Anderson I, et al. (2004) Combining TGF-beta inhibition and angiotensin II blockade results in enhanced antifibrotic effect. Kidney Int 66: 1774-1784.
114. Benigni A, Zoja C, Corna D, et al. (2003) Add-on anti-TGF-beta antibody to ACE inhibitor arrests progressive diabetic nephropathy in the rat. J Am Soc Nephrol 14: 1816-1824.
115. Benigni A, Zoja C, Campana M, et al. (2006) Beneficial effect of TGFbeta antagonism in treating diabetic nephropathy depends on when treatment is started. Nephron Exp Nephrol 104: e158-e168.
116. El Chaar M, Chen J, Seshan SV et al. (2007) Effect of combination therapy with enalapril and the TGF-beta antagonist 1D11 in unilateral ureteral obstruction. Am J Physiol Renal Physiol 292: F1291-F1301.
117. Sugaru E, Sakai M, Horigome K, et al. (2005) SMP-534 inhibits TGF-beta- induced ECM production in fibroblast cells and reduces mesangial matrix accumulation in experimental glomerulonephritis. Am J Physiol Renal Physiol 289: F998-F1004.
118. Petersen M, Thorikay M, Deckers M, et al. (2008) Oral administration of GW788388, an inhibitor of TGF-beta type I and II receptor kinases, decreases renal fibrosis. Kidney Int 73: 705-715.
119. Nguyen TQ, Goldschmeding R. (2008) Bone morphogenetic protein-7 and connective tissue growth factor: novel targets for treatment of renal fibrosis? Pharm Res, Feb 12 [Epub ahead of print] PMID: 18266088.
120. Ito Y, Aten J, Bende RJ, et al. (1998) Expression of connective tissue growth factor in human renal fibrosis. Kidney Int 53: 853-861.
121. Suzuki D, Toyoda M, Umezono T, et al. (2003) Glomerular expression of connective tissue growth factor mRNA in various renal diseases. Nephrology (Carlton) 8: 92-97.
122. Nonaka Takahashi S, Fujita T, Takahashi T, et al. (2008) TGF-beta1 and CTGF mRNAs are correlated with urinary protein level in IgA nephropathy. J Nephrol 21: 53-63.
123. Boor P, Sebekova K, Ostendorf T, et al. (2007) Treatment targets in renal fibrosis. Nephrol Dial Transplant 22: 3391-3407.